IRON
VENTE TOTALE: 66 000 titres (~5 028 507,00 $ US)
- Insiders
- Quisel John D
- Total bought
- —
- Total sold
- $5,028,507
- Last activity
- 2026-08-17
- Last synced
-
2026-08-23 00:12:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-26
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 21.940 | 21.171 | 17.056 | 8.791 | 6.740 | |
| Quick Ratio | 21.940 | 21.171 | 17.056 | 8.791 | 6.740 | |
| Solvency Ratio | -3.160 | -2.053 | -3.337 | -1.980 | -0.229 | |
| Cash Ratio | 2.488 | 8.253 | 16.810 | 8.619 | 6.558 | |
| Price To Earnings Ratio | -13.213 | -16.010 | -16.889 | -0.442 | -0.648 | |
| Price To Earnings Growth Ratio | -0.255 | -1.014 | 0.183 | -1.166 | -0.010 | |
| Forward Price To Earnings Growth Ratio | -0.255 | -1.014 | 0.183 | -1.166 | -0.010 | |
| Price To Earnings Diluted Ratio | -13.213 | -16.010 | -16.889 | -0.442 | -0.648 | |
| Price To Earnings Diluted Growth Ratio | -0.255 | -1.014 | 0.183 | -1.166 | -0.010 | |
| Price To Book Ratio | 3.788 | 3.946 | 3.735 | 0.117 | -0.363 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -15.457 | -18.534 | -17.525 | -0.488 | -0.845 | |
| Price To Operating Cash Flow Ratio | -15.537 | -18.634 | -17.546 | -0.489 | -0.847 | |
| Debt To Assets Ratio | 0.002 | 0.060 | 0.006 | 0.007 | 0.076 | |
| Debt To Equity Ratio | 0.003 | 0.068 | 0.006 | 0.008 | -0.110 | |
| Debt To Capital Ratio | 0.003 | 0.063 | 0.006 | 0.007 | -0.123 | |
| Long Term Debt To Capital Ratio | 0.002 | 0.060 | 0.000 | 0.000 | -0.006 | |
| Financial Leverage Ratio | 1.091 | 1.120 | 1.066 | 1.134 | -1.439 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.923 | -4.028 | -3.427 | -1.871 | -2.051 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.005 | 1.001 | 1.004 | 1.002 | |
| Debt Service Coverage Ratio | -49.383 | -189.911 | 0.000 | 0.000 | -4.719 | |
| Interest Coverage Ratio | -65.434 | -226.783 | 0.000 | 0.000 | -14.334 | |
| Short Term Operating Cash Flow Coverage Ratio | -295.242 | 0.000 | 0.000 | 0.000 | -5.507 | |
| Operating Cash Flow Coverage Ratio | -96.777 | -3.131 | -34.965 | -31.673 | -3.902 | |
| Capital Expenditure Coverage Ratio | -193.347 | -185.992 | -825.416 | -279.815 | -404.912 | |
| Dividend Paid And Capex Coverage Ratio | -193.347 | -185.992 | -825.416 | -279.815 | -404.912 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -13.050 | -14.665 | -12.209 | 3.693 | 1.707 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 21.940 | ▲0.769 | ▲6.800 |
| Quick Ratio | 21.940 | ▲0.769 | ▲6.800 |
| Solvency Ratio | -3.160 | ▼-1.107 | ▼-1.008 |
| Cash Ratio | 2.487 | ▼-5.766 | ▼-6.058 |
| Price To Earnings Ratio | -13.213 | ▲2.797 | ▼-3.773 |
| Price To Earnings Growth Ratio | -0.255 | ▲0.759 | ▲0.197 |
| Forward Price To Earnings Growth Ratio | -0.255 | ▲0.759 | ▲0.197 |
| Price To Earnings Diluted Ratio | -13.213 | ▲2.797 | ▼-3.773 |
| Price To Earnings Diluted Growth Ratio | -0.255 | ▲0.759 | ▲0.197 |
| Price To Book Ratio | 3.788 | ▼-0.157 | ▲1.544 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -15.457 | ▲3.077 | ▼-4.888 |
| Price To Operating Cash Flow Ratio | -15.537 | ▲3.097 | ▼-4.927 |
| Debt To Assets Ratio | 0.002 | ▼-0.058 | ▼-0.028 |
| Debt To Equity Ratio | 0.003 | ▼-0.065 | ▲0.008 |
| Debt To Capital Ratio | 0.003 | ▼-0.061 | ▲0.011 |
| Long Term Debt To Capital Ratio | 0.002 | ▼-0.058 | ▼-0.009 |
| Financial Leverage Ratio | 1.091 | ▼-0.029 | ▲0.496 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.923 | ▼-0.895 | ▼-1.663 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | ▼-0.000 | ▲0.002 |
| Debt Service Coverage Ratio | -49.383 | ▲140.528 | ▼-0.580 |
| Interest Coverage Ratio | -65.434 | ▲161.349 | ▼-4.124 |
| Short Term Operating Cash Flow Coverage Ratio | -295.242 | ▼-295.242 | ▼-235.092 |
| Operating Cash Flow Coverage Ratio | -96.777 | ▼-93.647 | ▼-62.688 |
| Capital Expenditure Coverage Ratio | -193.347 | ▼-7.355 | ▲184.549 |
| Dividend Paid And Capex Coverage Ratio | -193.347 | ▼-7.355 | ▲184.549 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -13.050 | ▲1.615 | ▼-6.145 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.80B | $1.75B | $1.29B | $20.7M | $23.3M | |
| Enterprise value | $2.71B | $1.59B | $930.7M | -$172.6M | -$57.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -15.04x | -16.91x | -12.67x | 4.08x | 2.09x | |
| EV / Free cash flow | -14.96x | -16.81x | -12.65x | 4.07x | 2.09x | |
| EV / EBITDA | -13.05x | -14.66x | -12.21x | 3.69x | 1.71x | |
| Net debt / EBITDA | 0.43x | 1.50x | 4.70x | 4.13x | 2.40x | |
| Current ratio | 21.94x | 21.17x | 17.06x | 8.79x | 6.74x | |
| Income quality | 0.85x | 0.86x | 0.96x | 0.90x | 0.77x | |
| Graham net-net | $21 | $16 | $15 | $165 | -$86 | |
| Tax burden | 100.2% | 100.3% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 101.7% | 100.5% | 100.0% | 100.0% | 106.4% | |
| Working capital | $767.3M | $470.3M | $344.2M | $175.9M | $77.1M | |
| Invested capital | $769.5M | $472.6M | $346.3M | $177.5M | $78.8M | |
| Return on assets | -26.3% | -22.0% | -20.8% | -23.4% | -38.9% | |
| Operating ROA | -36.2% | -30.0% | -32.1% | -32.4% | -61.4% | |
| Return on tangible assets | -26.3% | -22.0% | -20.8% | -23.4% | -38.9% | |
| Return on equity | -28.7% | -24.7% | -22.1% | -26.5% | 56.0% | |
| Return on invested capital | -30.6% | -27.4% | -26.2% | -26.7% | -36.7% | |
| Return on capital employed | -30.6% | -27.4% | -26.3% | -26.7% | -39.2% | |
| Earnings yield | -7.6% | -6.2% | -5.9% | -226.5% | -154.2% | |
| Free cash flow yield | -6.5% | -5.4% | -5.7% | -205.1% | -118.3% | |
| Capex / Op. cash flow | -0.5% | -0.5% | -0.1% | -0.4% | -0.2% | |
| Capex / Depreciation | 332.0% | 323.7% | 89.0% | 169.7% | 212.5% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+60.1%EV / Sales n/aEV / EBITDA ▲+11.0%EV / Op. cash flow ▲+1.862Earnings yield ▼-0.013
Profitability
Return on equity ▼-0.040Return on assets ▼-0.043Return on invested capital ▼-0.032Return on capital employed ▼-0.032Operating ROA ▼-0.062Income quality ▼-0.009Tax burden ▼-0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.769Net debt / EBITDA ▼-1.071Working capital ▲+296958000.000Invested capital ▲+296893000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+11917.6%EV / Sales n/aEV / EBITDA ▼-864.6%EV / Op. cash flow ▼-17.136Earnings yield ▲+1.467
Profitability
Return on equity ▼-0.847Return on assets ▲+0.126Return on invested capital ▲+0.061Return on capital employed ▲+0.085Operating ROA ▲+0.252Income quality ▲+0.085Tax burden ▲+0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+15.199Net debt / EBITDA ▼-1.968Working capital ▲+690197000.000Invested capital ▲+690705000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-22 Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON NEW YORK, Aug. 22, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-08-21 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-08-18 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-08-17 Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON PR Newswire
- 2026-08-17 Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-08-14 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
- 2026-08-12 Bolt Metals to Rebrand as 26 Metals Inc. and Adopt the Ticker "IRON," Highlighting Its Focus on Flagship Florália Iron Project in Brazil''s Iron Quadrangle New name and symbol mark the Company''s transformation into a focused, near-term iron developer — anchored by a high-grade, low-carbon, infrastructure-rich project in the heart of one of the world''s premier iron ore districts. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK) is pleased to announce that it will change its name to 26 Metals Inc. and begin trading under the new ticker symbol "IRON" on the Canadian Securities Exchange (the "CSE") at market open on August 19, 2026.
- 2026-08-09 ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON New York, New York--(Newsfile Corp. - August 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-08-08 ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON New York, New York--(Newsfile Corp. - August 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-08-07 Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.